Clinical Trials Browser

Phase 4 × INDUSTRY × Melanoma × Clear all

Carcinoma, Non-Small-Cell Lung, Glioma, Lung Neoplasms, Melanoma

NCT07459543 2026-03-09

A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India

Phase 4 Not yet recruiting

30 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT03715205 2025-08-29

Keynote-593

Phase 4 Completed

150 enrolled 14 charts

DermatologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Phase 4 Completed

337 enrolled 8 charts

DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT01856023 2023-12-05

PROCLIVITY02

Phase 4 Terminated

29 enrolled 9 charts

Dermatologic

Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT00414765 2021-06-08

Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma

Phase 4 Completed

26 enrolled 7 charts

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT01683188 2021-02-01

PROCLIVITY01

Phase 4 Terminated

53 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT01898585 2020-01-07

An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma

Phase 4 Completed

60 enrolled

Dermatologic

Melanoma

Clinical Trials

Dabrafenib and/or Trametinib Rollover Study

A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India

Keynote-593

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

PROCLIVITY02

Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma

PROCLIVITY01

An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma